Alpha Teknova, a provider of reagents for biopharmaceutical applications, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
Alpha Teknova is a leading provider of critical reagents that enable the discovery, research, development and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. The company offers three primary product types: pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. As of March 31, 2021, Alpha Teknova had over 3,000 active customers.
The Hollister, CA-based company was founded in 2000 and booked $34 million in sales for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol TKNO. Alpha Teknova filed confidentially on April 5, 2021. Cowen, and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
